Join us to explore how New Approach Methodologies (NAMs) are shaping the future of human health safety testing. Industry and government leaders will share insights on how innovative methods, ranging from computational models to organ-on-a-chip systems, are improving human safety predictions while reducing or replacing animal use. Before the panel, you’ll get a chance to network, tour ATCC’s Operations Hallway, and enjoy light refreshments and snacks.

Note: For ATCC security purposes, all attendees will be asked to provide their name, organization, and email address when registering and bring a photo ID to the event for confirmation. If attendees are interested in touring ATCC’s Operations Hallway, they will need to wear closed shoes.

Program

5:30 p.m. – 6:15 p.m.  Networking & Tours through ATCC’s Operations Hallway
6:15 p.m. – 6:30 p.m.  Welcome and Introductions
6:30 p.m. – 7:15 p.m.  NAMs-focused Panel Discussion and Q&A
7:15 p.m. – 7:30 p.m.  Wrap-up and Continued Networking

Speaker Bios

Morgan Halman, PhD, Director US at MIMETAS

Morgan is the Director US at MIMETAS, a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. In her current role, she leads the US site in Gaithersburg, MD, which produces off-the-shelf OrganoReady® tissue and organoid models to support customers across North America. Before joining Mimetas, she completed an ORISE postdoctoral fellowship at FDA and earned her PhD in nanoscale science from the University of North Carolina at Charlotte.

Carolina Lucchesi, PhD, Principal Scientist & Head of Microphysiological Systems at ATCC

Carolina is a Principal Scientist leading the Microphysiological Systems program at ATCC. Dr. Lucchesi received her PhD in cellular and molecular biology from the University of Campinas in Brazil and has over 20 years of experience in tissue engineering and organ-on-chip technology. In her current role, Dr. Lucchesi leads the MPS program, bringing new capabilities in the use of advanced 3D models and developing existing and new content to be applied in state-of-the-art technologies.

Margaret Ochocinska, PhD, Program Director at National Institutes of Health

Margaret is a Program Leader in the NIH Office of Strategic Coordination where she leads the Complement-Animal Research In Experimentation (Complement-ARIE) Program to accelerate the development, standardization, validation, and use of human-based New Approach Methodologies (NAMs). She recently launched the NIH-FNIH Public-Private-Partnership effort to establish the Complement-ARIE Validation and Qualification Network for NAMs Adoption and Implementation. Previously, she served as Program Director in the Translational Blood Science and Resources Branch in the Division of Blood Diseases and Resources at the National Heart, Lung, and Blood Institute (NHLBI) and a Health Program Specialist in the Office of Translational Research at the National Institute of Neurological Disorders and Stroke (NINDS). Dr. Ochocinska received her PhD in neuroscience from the University of Michigan, Ann Arbor, and completed a postdoctoral fellowship at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), where she worked on identifying mediators of photoreceptor degeneration.

Pricing Information

• Members: Free
• Non-members*: $15

*Not a Member? Click here to purchase a WIB membership and gain access to our video library, mentorship opportunities, and more.

Please read WIB's Code of Conduct and Refund Policy.

Note: A confirmation email will be sent after registration has been completed. 

Registration Deadline

September 20, 2026

Maximum Capacity

75

Parking Information

Parking is available on site.